Lipidomic analysis coupled with machine learning identifies unique urinary lipid signatures in patients with interstitial cystitis/bladder pain syndrome

被引:0
作者
Takuya Iwaki [1 ]
Makoto Kurano [2 ]
Masahiko Sumitani [3 ]
Aya Niimi [4 ]
Akira Nomiya [1 ]
Jun Kamei [5 ]
Satoru Taguchi [1 ]
Yuta Yamada [1 ]
Yusuke Sato [1 ]
Masaki Nakamura [1 ]
Daisuke Yamada [6 ]
Tomonori Minagawa [7 ]
Hiroshi Fukuhara [1 ]
Haruki Kume [8 ]
Yukio Homma [9 ]
Yoshiyuki Akiyama [1 ]
机构
[1] Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo
[2] Department of Urology, Chiba Tokushukai Hospital, Chiba
[3] Department of Clinical Laboratory Medicine, The University of Tokyo, Tokyo
[4] Department of Pain and Palliative Medicine, The University of Tokyo Hospital, Tokyo
[5] Department of Urology, Japan Organization of Occupational Health and Safety, Kanto Rosai Hospital, Kanagawa
[6] Department of Urology, Tokyo Metropolitan Tama Medical Center, Tokyo
[7] Department of Urology, NTT Medical Center Tokyo, Tokyo
[8] Department of Urology, Shinshu University School of Medicine, Nagano
[9] Department of Urology, Kyorin University School of Medicine, Tokyo
[10] Department of Interstitial Cystitis Medicine, Kyorin University School of Medicine, Tokyo
基金
日本学术振兴会;
关键词
Biomarker; Bladder pain syndrome; Hunner; IC; IC/BPS; Interstitial cystitis; Learning; Lipidomics; Machine; Urinary;
D O I
10.1007/s00345-025-05628-y
中图分类号
学科分类号
摘要
Purpose: To identify biomarkers for diagnosis and classification of interstitial cystitis/bladder pain syndrome (IC/BPS) by urinary lipidomics coupled with machine learning. Methods: Urine samples from 138 patients with IC/BPS, including 116 with Hunner lesion (HL) and 22 with no HL, and 71 controls were assessed by lipid chromatography-tandem mass spectrometry. Single and paired lipid analyses of differentially expressed lipids in each group were conducted to assess their diagnostic ability. Machine learning models were constructed based on the identified urinary lipids and patient demographic data, and a five-fold cross-validation method was applied for internal validation. Levels of urinary lipids were adjusted to account for urinary creatinine levels. Results: A total of 218 urinary lipids were identified. Single lipid analysis revealed that urinary levels of C24 ceramide and LPC (14:0) distinguished HL and no HL, with an area under the receiver operating characteristics curve of 0.792 and 0.656, respectively. Paired lipid analysis revealed that summed urinary levels of C24 ceramide and LPI (18:3), and subtraction of PG (36:5) from PC (38:2) distinguished HL and no HL even more accurately, with an area under the curve of 0.805 and 0.752, respectively. A machine learning model distinguished HL and no HL, with the highest area under the curve being 0.873 and 0.750, respectively. Limitations include the opaque black box nature of machine learning techniques. Conclusions: Urinary levels of C24 ceramide, along with those of C24 ceramide plus LPI (18:3), could be potential biomarkers for HL. Machine learning-coupled urinary lipidomics may play an important role in the next-generation AI- driven diagnostic systems for IC/BPS. © The Author(s) 2025.
引用
收藏
相关论文
共 26 条
  • [1] Clemens J.Q., Erickson D.R., Varela N.P., Et al., Diagnosis and treatment of interstitial cystitis/bladder pain syndrome, J Urol, 208, pp. 34-42, (2022)
  • [2] Homma Y., Akiyama Y., Tomoe H., Et al., Clinical guidelines for interstitial cystitis/bladder pain syndrome, Int J Urol, 27, pp. 578-589, (2020)
  • [3] Akiyama Y., Hanno P., Phenotyping of interstitial cystitis/bladder pain syndrome, Int J Urol, 26, pp. 17-19, (2019)
  • [4] Akiyama Y., Maeda D., Katoh H., Et al., Molecular taxonomy of interstitial cystitis/bladder pain syndrome based on whole transcriptome profiling by Next-Generation RNA sequencing of bladder mucosal biopsies, J Urol, 202, pp. 290-300, (2019)
  • [5] Akiyama Y., Luo Y., Hanno P.M., Et al., Interstitial cystitis/bladder pain syndrome: the evolving landscape, animal models and future perspectives, Int J Urol, 27, pp. 491-503, (2020)
  • [6] Akiyama Y., Harada K., Miyakawa J., Et al., Th1/17 polarization and potential treatment by an anti-interferon-gamma DNA aptamer in Hunner-type interstitial cystitis, iScience, 26, (2023)
  • [7] Akiyama Y., Sonehara K., Maeda D., Et al., Genome-wide association study identifies risk loci within the major histocompatibility complex region for Hunner-type interstitial cystitis, Cell Rep Med, 4, (2023)
  • [8] Lai H.H., Newcomb C., Harte S., Et al., Comparison of deep phenotyping features of UCPPS with and without Hunner lesion: A MAPP-II research network study, Neurourol Urodyn, 40, pp. 810-818, (2021)
  • [9] Akiyama Y., Homma Y., Immunomodulatory therapies for interstitial cystitis/bladder pain syndrome, Curr Bladder Dysfunct Rep, 15, pp. 186-191, (2020)
  • [10] Han X., Gross R.W., The foundations and development of lipidomics, J Lipid Res, 63, (2022)